Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $32.8 billion.

  • Teva Pharmaceutical Industries' Total Liabilities fell 229.72% to $32.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.8 billion, marking a year-over-year decrease of 229.72%. This contributed to the annual value of $32.8 billion for FY2025, which is 229.72% down from last year.
  • Teva Pharmaceutical Industries' Total Liabilities amounted to $32.8 billion in Q4 2025, which was down 229.72% from $32.6 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Total Liabilities' 5-year high stood at $38.0 billion during Q1 2021, with a 5-year trough of $32.1 billion in Q1 2025.
  • In the last 5 years, Teva Pharmaceutical Industries' Total Liabilities had a median value of $35.3 billion in 2023 and averaged $35.1 billion.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 192.17% in 2024, then crashed by 875.39% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Total Liabilities stood at $36.4 billion in 2021, then dropped by 2.77% to $35.4 billion in 2022, then fell by 0.17% to $35.4 billion in 2023, then fell by 4.94% to $33.6 billion in 2024, then fell by 2.3% to $32.8 billion in 2025.
  • Its last three reported values are $32.8 billion in Q4 2025, $32.6 billion for Q3 2025, and $33.3 billion during Q2 2025.